Vigil Neuroscience to Present at Evercore ISI 6th Annual HealthCONx Conference

Rhea-AI Summary

Vigil Neuroscience, Inc. (VIGL) to participate in fireside chat at Evercore ISI 6th Annual HealthCONx Conference

WATERTOWN, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President and Chief Executive Officer, and David Gray, Ph.D., Chief Science Officer, will participate in a fireside chat at the Evercore ISI 6^th Annual HealthCONx Conference on Tuesday, November 28, at 3:50 p.m. E.T.

To register for the live event, please click here. The webcast will also be available on the Company’s website on the “Events & Presentations” page in the “Investors” section. An archived webcast will be available for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website at https://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:
Leah Gibson
Vice President, Investor Relations & Corporate Communications
Vigil Neuroscience, Inc.
lgibson@vigilneuro.com

Media Contact:
Megan McGrath
MacDougall Advisors
mmcgrath@macdougall.bio

FAQ

What is the latest announcement from Vigil Neuroscience, Inc. (VIGL)?

Vigil Neuroscience, Inc. (VIGL) announced that its President and CEO, Ivana Magovčević-Liebisch, and Chief Science Officer, David Gray, will participate in a fireside chat at the Evercore ISI 6th Annual HealthCONx Conference on November 28.

When and where will the fireside chat take place?

The fireside chat will take place on Tuesday, November 28, at 3:50 p.m. E.T. It will be available for live registration and webcast on the Company’s website.

How long will the webcast be available for viewing?

The webcast will be available for approximately 90 days following the presentation.

How can I register for the live event?

To register for the live event, you can click on the provided link on the Company’s website.

Where can I find the archived webcast after the presentation?

The archived webcast will also be available on the Company’s website on the 'Events & Presentations' page in the 'Investors' section.